Erasca, Inc. (NASDAQ:ERAS – Get Free Report)’s stock price passed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $14.89 and traded as low as $13.60. Erasca shares last traded at $13.89, with a volume of 8,789,965 shares trading hands.
Erasca News Roundup
Investors following ERAS have been watching these news items:
- Positive Sentiment: Erasca and BMS will evaluate ERAS-0015 with navlimetostat in a clinical study for pancreatic cancer. The partnership brings a major pharmaceutical company into testing the combination and may strengthen investor confidence in the program; clinical results are still needed to establish its potential. Erasca and BMS clinical collaboration
- Positive Sentiment: Analyst attention has also increased: Leerink Partners initiated coverage, and a separate report said estimated fair value edged higher amid optimism about ERAS-0015. The headlines do not specify Leerink’s rating or target, so the impact of its coverage is unclear. Leerink Partners coverage initiation Erasca fair-value report
- Neutral Sentiment: A separate report covered U.S. lawmakers’ broader push for the biotech sector to compete with China. It may be relevant to the industry, but the article listing does not indicate a direct effect on Erasca. STAT article on U.S. biotech policy
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. Leerink Partners started coverage on shares of Erasca in a report on Tuesday. They set an “outperform” rating and a $35.00 target price for the company. Guggenheim upped their target price on Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 13th. HC Wainwright raised their price target on Erasca from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a report on Tuesday, September 8th. Finally, Bank of America upped their price objective on shares of Erasca from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.17.
Read Our Latest Stock Analysis on ERAS
Erasca Trading Up 3.3%
The stock has a market cap of $4.99 billion, a P/E ratio of -14.36 and a beta of 0.68. The stock’s fifty day moving average price is $14.81 and its 200 day moving average price is $15.33.
Erasca (NASDAQ:ERAS – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). As a group, sell-side analysts forecast that Erasca, Inc. will post -0.51 earnings per share for the current year.
Hedge Funds Weigh In On Erasca
Large investors have recently made changes to their positions in the business. Wealthcare Advisory Partners LLC lifted its holdings in shares of Erasca by 5.0% during the second quarter. Wealthcare Advisory Partners LLC now owns 15,924 shares of the company’s stock valued at $292,000 after purchasing an additional 756 shares in the last quarter. Nykredit A S purchased a new position in shares of Erasca during the second quarter valued at approximately $29,000. Allworth Financial LP purchased a new position in shares of Erasca during the second quarter valued at approximately $34,000. EverSource Wealth Advisors LLC lifted its position in Erasca by 77.8% during the first quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company’s stock valued at $69,000 after purchasing an additional 1,859 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in Erasca by 9.3% in the third quarter. ProShare Advisors LLC now owns 39,799 shares of the company’s stock worth $583,000 after purchasing an additional 3,391 shares during the last quarter. 67.78% of the stock is currently owned by hedge funds and other institutional investors.
About Erasca
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
See Also
- Five stocks we like better than Erasca
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
